Sort
48,018 grants matching “immunotherapy”
Ethnicity-determined T cell responses and GARP/TGFbeta1 signaling in prostate cancer
$370,628Xiaolin Zi · University Of California-Irvine · R01 · FY2022 · CA
T Cell Targeting for GVHD
$370,608Bruce R. Blazar · University Of Minnesota · R01 · FY2010 · HL
Molecular Control of Plasmacytoid Dendritic Cell Development and Function
$370,602Boris Reizis · Columbia University Health Sciences · R01 · FY2013 · AI
Mechanisms Underlying the Role of Interleukin-7 in Type 1 Diabetes
$370,594Hans Peter Dooms · Boston University Medical Campus · R01 · FY2018 · DK
Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors
$370,575Timothy Anthony Yap · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
Improving Diagnosis and Management of Cancer Immunotherapy-Induced Hypophysitis
$370,575Patrizio Caturegli · Johns Hopkins University · R01 · FY2017 · CA
Harnessing Aurora kinase inhibitionâinduced cell death to enhance immunotherapy in HPVâdriven cancers
$370,575Faye Johnson · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
Mechanism-rooted therapeutic strategies for immune-related toxicities induced by checkpoint inhibitors
$370,575Roza Insafetdinovna Nurieva · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer
$370,575Ferdinandos Skoulidis · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Mechanism-rooted therapeutic strategies for immune-related toxicities induced by checkpoint inhibitors
$370,575Roza Insafetdinovna Nurieva · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Bayesian Methods for Complex Precision Biotherapy Trials in Oncology
$370,575Peter F Thall · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer
$370,575Rafet Basar · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancer
$370,575Ferdinandos Skoulidis · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Dissecting the source and mechanisms of IL-17-mediated modulation of pancreatic tumorigenesis
$370,575Florencia McAllister · University Of Tx Md Anderson Can Ctr · R37 · FY2022 · CA
Dissecting the source and mechanisms of IL-17-mediated modulation of pancreatic tumorigenesis
$370,575Florencia McAllister · University Of Tx Md Anderson Can Ctr · R37 · FY2020 · CA
Harnessing Aurora kinase inhibitionâinduced cell death to enhance immunotherapy in HPVâdriven cancers
$370,575Faye Johnson · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA
Paradoxical roles of tumor lymphangiogenesis on tumor immunity and implications for immunotherapy - Resubmission 01
$370,575Melody A Swartz · University Of Chicago · R01 · FY2020 · CA
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer
$370,575Ferdinandos Skoulidis · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
Improving Diagnosis and Management of Cancer Immunotherapy-Induced Hypophysitis
$370,575Patrizio Caturegli · Johns Hopkins University · R01 · FY2020 · CA
Paradoxical roles of tumor lymphangiogenesis on tumor immunity and implications for immunotherapy - Resubmission 01
$370,575Melody A Swartz · University Of Chicago · R01 · FY2018 · CA
TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer
$370,575Rafet Basar · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Improving Diagnosis and Management of Cancer Immunotherapy-Induced Hypophysitis
$370,575Patrizio Caturegli · Johns Hopkins University · R01 · FY2016 · CA
Dissecting the source and mechanisms of IL-17-mediated modulation of pancreatic tumorigenesis
$370,575Florencia McAllister · University Of Tx Md Anderson Can Ctr · R37 · FY2021 · CA
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
$370,575Juan Fueyo · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer
$370,575Ferdinandos Skoulidis · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA